RBN-2397 Inhibitor

Name: RBN-2397 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5753806
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5753806

RBN-2397 is a potent, selective and orally active accross species NAD+ competitive PARP7 inhibitor with IC50 less than 3nM. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

RBN-2397, Inhibitor

Full Product Name

RBN-2397

Product Gene Name

RBN-2397, inhibitor

Form/Format

Solid. Powder

Purity/Purification

98.68%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

523.43

Solubility

DMSO: 247mg/mL (471.89mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C20H23F6N7O3

SMILES

FC(F)(F)c1cnc(nc1)N2CCN(CC2)C(=O)CCOC[C@H](C)NC=3C=NNC(=O)C=3C(F)(F)F

CAS Number

2381037-82-5

Target & IC50

PARP-7: ic50 1nM (kd)

In Vitro

Inhibition of PARP7 with RBN-2397 can potently inhibit the growth of cancer cells and restore interferon signaling, effectively releasing the brake cancer uses to hide from the immune system and suppress both innate and adaptive immune mechanisms. RBN-2397 inhibits cells proliferation (IC50 value of 20nM in NCI-H1373 lung cancer cells), shows a restoration of type I IFN response by an increase in STAT1 phosphorylation as a dose-dependent manner in NCI-H1373 human lung cancer cells, and inhibits cell MARylation in a cell biochemial assay with an EC50 value of 1nM[2].

Product Categories/Family for RBN-2397, inhibitor

Chromatin/Epigenetic; DNA Damage/DNA Repair

Product References and Citations for RBN-2397, inhibitor

RBN-2397-Inhibiting PARP7, a Key monoPARP Cancer Dependency
RBN-2397-Inhibiting PARP7, a Key monoPARP Cancer Dependency
Melissa Vasbinder, et al. RBN-2397: A First-in-Class PARP7 Inhibitor Targeting a Newly Discovered Cancer Vulnerability in Stress-Signaling Pathways.
Melissa Vasbinder, et al. RBN-2397: A First-in-Class PARP7 Inhibitor Targeting a Newly Discovered Cancer Vulnerability in Stress-Signaling Pathways.

Other Notes

Small volumes of RBN-2397, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for RBN-2397 purchase

MBS5753806 is an inhibitor targeting RBN-2397.